|
Index | - | P/E | - | EPS (ttm) | -1.56 | Insider Own | 3.30% | Shs Outstand | 44.32M | Perf Week | 15.38% |
Market Cap | 2.00B | Forward P/E | - | EPS next Y | -1.48 | Insider Trans | -46.30% | Shs Float | 43.12M | Perf Month | 6.83% |
Income | -68.80M | PEG | - | EPS next Q | -0.49 | Inst Own | 80.70% | Short Float | 5.80% | Perf Quarter | 15.50% |
Sales | 49.70M | P/S | 40.27 | EPS this Y | -9.30% | Inst Trans | 9.92% | Short Ratio | 5.57 | Perf Half Y | 79.55% |
Book/sh | 5.40 | P/B | 8.31 | EPS next Y | 22.00% | ROA | -20.80% | Target Price | 47.71 | Perf Year | - |
Cash/sh | 6.05 | P/C | 7.42 | EPS next 5Y | 52.70% | ROE | -26.40% | 52W Range | 15.38 - 47.73 | Perf YTD | 79.41% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | -17.10% | 52W High | 1.86% | Beta | - |
Dividend % | - | Quick Ratio | 15.30 | Sales past 5Y | - | Gross Margin | 50.20% | 52W Low | 216.12% | ATR | 2.55 |
Employees | 234 | Current Ratio | 16.00 | Sales Q/Q | 6.40% | Oper. Margin | - | RSI (14) | 69.95 | Volatility | 6.32% 5.55% |
Optionable | Yes | Debt/Eq | 0.21 | EPS Q/Q | 33.20% | Profit Margin | - | Rel Volume | 1.81 | Prev Close | 44.87 |
Shortable | Yes | LT Debt/Eq | 0.21 | Earnings | Aug 04 AMC | Payout | - | Avg Volume | 449.63K | Price | 48.62 |
Recom | 2.00 | SMA20 | 14.22% | SMA50 | 26.65% | SMA200 | 50.58% | Volume | 161,727 | Change | 8.36% |
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite